UBS O'Connor’s Protalix BioTherapeutics PLX Stock Holding History

UBS O'Connor’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-445,171	Closed	-$1.99M	–	916
2021 Q1	$1.99M	Buy	445,171 +295,171	+197%	+$1.37M	0.03%	475
2020 Q4	$544K	Sell	150,000 -150,000	-50%	-$538K	0.01%	482
2020 Q3	$1.16M	Sell	300,000 -372,035	-55%	-$1.35M	0.03%	216
2020 Q2	$2.55M	Buy	+672,035	New	+$2.3M	0.06%	208
2018 Q1	–	Sell	-32,448	Closed	-$215K	–	351
2017 Q4	$215K	Hold	32,448	–	–	﹤0.01%	274
2017 Q3	$188K	Hold	32,448	–	–	﹤0.01%	316
2017 Q2	$272K	Buy	+32,448	New	+$305K	﹤0.01%	356
2017 Q1	–	Sell	-400,000	Closed	-$1.78M	–	475
2016 Q4	$1.78M	Buy	+400,000	New	+$1.79M	0.03%	316

Other funds holding PLX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Walleye Trading New York $87.6B AUM 68.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

UBS O'Connor's PLX Position: Q2 2021 in Review

UBS O'Connor sold out of Protalix BioTherapeutics (PLX) in Q2 2021, closing a stake of 445,171 shares — an estimated $1.99M sold.

UBS O'Connor first reported a position in PLX in Q4 2016 and held it in 8 quarters. The position peaked at $2.55M in Q2 2020. 33 funds tracked by Wall St. Rank hold PLX as of Q2 2021.

UBS O'Connor reported no remaining Protalix BioTherapeutics position as of Q2 2021 after selling out during the quarter.
UBS O'Connor sold 445,171 Protalix BioTherapeutics shares in Q2 2021, an estimated $1.99M.
UBS O'Connor first reported a position in Protalix BioTherapeutics in Q4 2016 and held it in 8 quarters.
UBS O'Connor's Protalix BioTherapeutics position peaked at $2.55M in Q2 2020.
33 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2021.

Based on UBS O'Connor's 13F filing for Q2 2021, filed 13 Aug 2021.